Xin Lang Cai Jing·2025-12-11 05:37Group 1 - The core viewpoint of the news is that Junshi Biosciences has shown significant trading activity, with a notable financing balance and changes in stockholder composition [1][2] Group 2 - On December 10, Junshi Biosciences' stock increased by 0.58%, with a trading volume of 173 million yuan. The financing buy-in amount was 10.57 million yuan, while the financing repayment was 12.40 million yuan, resulting in a net financing outflow of 1.83 million yuan [1] - As of December 10, the total financing and securities lending balance for Junshi Biosciences was 1.375 billion yuan, with the financing balance at 1.361 billion yuan, accounting for 4.89% of the circulating market value, which is above the 70th percentile of the past year [1] - In terms of securities lending, on December 10, there were no shares repaid, with 2,807 shares sold short, amounting to 101,900 yuan at the closing price. The remaining short selling volume was 388,900 shares, with a short selling balance of 14.12 million yuan, exceeding the 90th percentile of the past year [1] Group 3 - Junshi Biosciences, established on December 27, 2012, and listed on July 15, 2020, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs. The main revenue sources are drug sales (90.67%), technology licensing (8.74%), and technical services (0.59%) [2] - As of September 30, the number of shareholders for Junshi Biosciences was 35,900, an increase of 15.17% from the previous period, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2] - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a year-on-year increase of 35.72% [2] - As of September 30, 2025, among the top ten circulating shareholders, E Fund's Science and Technology Innovation Board 50 ETF held 19.39 million shares, a decrease of 2.82 million shares from the previous period, while Huaxia's Science and Technology Innovation Board 50 ETF held 18.97 million shares, a decrease of 1.07 million shares [2]